Octapharma has begun enrolling patients in its Phase II/III trial of GAM-27 for the treatment of relapsing multiple sclerosis (RMS). Through intravenous administration of immunoglobulin (Octagam 5%), the study seeks to support the overall clinical benefit of a lower annualized relapse rate in patients where first-line treatment is not suitable. This randomized, active-controlled study aims to confirm preliminary results that suggested it is possible to identify potential responders to treatment...